What Is Vitamin K2

Vitamin K2, also called menaquinone, is a fat-soluble vitamin responsible for activating proteins that regulate calcium metabolism throughout the body. It ensures calcium is deposited in bone and dental tissue while preventing its accumulation in arteries, kidneys, and other soft tissues. Found naturally in fermented foods, organ meats, and certain animal products, K2 is distinct from Vitamin K1, which primarily supports blood coagulation in the liver.

Calcium is essential for skeletal strength, but when it accumulates in the wrong places, particularly in arterial walls, it contributes to cardiovascular disease, the leading cause of death worldwide. Vitamin K2 sits at the intersection of two major age-related concerns: progressive bone loss and vascular calcification. Both conditions accelerate with age and share a common regulatory mechanism that depends on adequate K2 status.

The Western diet tends to be low in K2 compared to K1. Populations that consume fermented soy products (such as natto) or high amounts of aged cheeses and pastured animal fats typically have higher K2 intakes. Subclinical K2 insufficiency may be widespread without producing obvious symptoms, since the body prioritizes K1-dependent clotting functions over the K2-dependent calcium-routing functions. This silent insufficiency may contribute to the parallel rise of osteoporosis and arterial calcification seen in aging populations.

Vitamin K2 functions as a cofactor for the enzyme gamma-glutamyl carboxylase, which converts specific glutamic acid residues in certain proteins into gamma-carboxyglutamic acid (Gla) residues. This carboxylation step is what "activates" these proteins, giving them the ability to bind calcium. The two most important K2-dependent proteins are osteocalcin and matrix Gla protein (MGP).

Osteocalcin, produced by osteoblasts (bone-building cells), must be carboxylated to effectively bind calcium and incorporate it into the hydroxyapatite crystal lattice of bone. When K2 is insufficient, a larger fraction of osteocalcin circulates in its undercarboxylated (inactive) form, and calcium integration into bone is impaired. Undercarboxylated osteocalcin (ucOC) levels in the blood can serve as a functional marker of K2 status.

Matrix Gla protein operates in the walls of blood vessels and cartilage, where its activated form acts as a local inhibitor of calcification. Without adequate K2, MGP remains uncarboxylated and unable to prevent calcium phosphate crystals from forming in arterial smooth muscle. This mechanism explains why K2 status appears linked to both bone density and cardiovascular health simultaneously. The vitamin is absorbed in the small intestine alongside dietary fat, and the longer-chain forms (such as MK-7) are transported on lipoproteins, giving them extended circulation time and broader tissue distribution compared to MK-4, which is rapidly taken up and cleared.

Vitamin K2 encompasses a family of compounds called menaquinones, designated MK-4 through MK-13 based on the length of their isoprenoid side chain. The two forms most relevant to supplementation are MK-4 and MK-7. MK-4 is the form synthesized endogenously from K1 in certain tissues and is found in animal products such as egg yolks, butter, and organ meats. It has a short half-life (a few hours), requiring multiple daily doses or a single large dose, and has been studied primarily at pharmacological levels (45 mg per day) for osteoporosis in Japan.

MK-7 is produced by bacterial fermentation, most abundantly in natto (fermented soybeans). Its longer side chain gives it a half-life of approximately two to three days, allowing once-daily dosing to maintain stable blood levels. MK-7 is the form used in most Western supplements and the majority of recent clinical trials. It is available as softgels, capsules, and liquid drops, typically formulated with a small amount of fat or oil to aid absorption. Some products combine MK-7 with vitamin D3 and sometimes calcium in a single formulation. Sublingual and liposomal delivery formats exist but have not been shown to offer meaningful absorption advantages over standard oil-based softgels taken with food.

For MK-7, the most commonly studied and recommended dose range is 100 to 200 mcg per day. The three-year trial that demonstrated both bone and vascular benefits used 180 mcg daily. Some practitioners recommend higher doses (up to 360 mcg) for individuals with established arterial calcification or significant osteoporosis, though dose-response data at these levels is limited.

MK-4 is typically used at much higher doses, often 15 mg three times daily (45 mg total) in the Japanese clinical context, where it is classified as a pharmaceutical for osteoporosis. Lower doses of MK-4 (around 1 to 5 mg) are sometimes included in multi-nutrient supplements, though the evidence base for these intermediate doses is thin. Because K2 is fat-soluble, taking it with a meal that contains dietary fat improves absorption. There is no established upper limit for K2 intake. People supplementing with high-dose vitamin D (5,000 IU or more per day) may benefit from proportionally higher K2 intake to ensure adequate carboxylation capacity, though the exact ratio remains a matter of clinical judgment rather than settled evidence.

When selecting a K2 supplement, several quality indicators are worth evaluating. For MK-7, look for products that specify the use of the all-trans form rather than the cis isomer; the trans configuration is the biologically active form, while cis-MK-7 has little to no physiological activity. Some lower-cost supplements contain a mixture of both isomers, reducing effective potency. Reputable brands typically state "all-trans MK-7" or reference a branded ingredient with documented trans content.

Third-party testing through organizations such as NSF International, USP, or independent labs like ConsumerLab adds confidence that the product contains what the label claims and is free of contaminants. Because K2 can degrade with exposure to light and heat, products packaged in opaque or amber containers tend to maintain stability better than those in clear packaging. Soy-derived MK-7 (from natto fermentation) is the most common source; individuals with soy allergies should verify whether the final product contains residual soy protein, though most fermentation-derived MK-7 is highly purified. Chickpea-fermented MK-7 is available as a soy-free alternative.

The largest body of observational evidence comes from the Rotterdam Study, which followed several thousand older adults and found that higher dietary vitamin K2 intake was associated with significantly reduced cardiovascular mortality and aortic calcification, while K1 intake showed no such association. Similar findings emerged from subsequent European cohort studies. Japanese clinical trials have evaluated high-dose MK-4 (45 mg per day) for osteoporosis treatment and found reductions in fracture incidence, though these studies used doses far beyond typical supplementation levels and were conducted primarily in postmenopausal women.

For MK-7, a three-year randomized controlled trial in healthy postmenopausal women found that 180 mcg per day improved bone mineral content and reduced age-related loss of bone strength as measured by femoral neck geometry, while also improving vascular elasticity. Despite these results, large-scale, long-duration interventional trials in diverse populations are still lacking. The evidence for K2's role in activating MGP and osteocalcin is mechanistically well-established, but the clinical magnitude of benefit from supplementation, particularly for people without overt deficiency, remains an area of active investigation. Most regulatory bodies have not established specific K2 intake recommendations separate from K1.

Vitamin K2 at typical supplemental doses (up to 200 mcg of MK-7 or 45 mg of MK-4 per day) has demonstrated a favorable safety profile in available trials, with no significant adverse effects reported. The most important contraindication is concurrent use of warfarin or other vitamin K antagonist anticoagulants, because K2 directly opposes the drug's mechanism, potentially altering INR and clotting status. People on direct oral anticoagulants (DOACs) such as apixaban or rivarfaban are generally less affected, but should still discuss supplementation with their prescriber. High doses of K2 have not shown toxicity in studies to date, and no tolerable upper intake level has been established by major regulatory agencies.